Background
==========

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency in adults. CVID clinically presents with a history of recurrent infections at mucous membranes which is the consequence of a marked hypogammaglobulinemia \[[@B1]\]. The clinical course of CVID is complicated by a plethora of systemic immunopathology including autoimmunity, lymphoproliferation, malignancy and sarcoid-like granulomas.

CVID affects males and females equally and usually manifests in the second or third decade of life. A second peak of onset exists in childhood between the ages of 2 and 5 years \[[@B2],[@B3]\]. The prevalence of CVID in the Western hemisphere is estimated to be approximately 1: 25.000 \[[@B1],[@B4]\].

The majority of CVID cases are sporadic, while approximately 10 to 20% of CVID cases show at least one additional family member affected either by CVID or selective IgA deficiency (sIgAD) \[[@B5],[@B6]\]. Most multiplex CVID families show an autosomal dominant mode of inheritance but about 20% present with a recessive trait. CVID and sIgAD deficiency may concur in a single kindred and sIgAD may show progression to CVID in some affected individuals over time \[[@B6]-[@B8]\].

Early association and more recent genetic linkage studies have revealed several putative susceptibility loci for CVID/sIgAD. While most of these studies combined families with sIgAD and CVID, Vořechovský et al analyzed sIgA-deficient families separately and identified a susceptibility locus within the HLA region on chromosome 6p termed \"*IGAD1*\" \[[@B9]\]. In 2003, the same group reported that certain *HLA-DQ/DR*haplotypes and not other putative candidate genes within the *IGAD1*region confer the protection from or susceptibility to sIgAD and CVID \[[@B10]\]. The same study suggested that the best prospects for non-MHC susceptibility loci could be found on chromosomes 4p, 12p and 14q, but none of these three loci reached statistical significance.

We were recently able to demonstrate genetic linkage to chromosome 16q for autosomal dominant CVID in this cohort of families \[[@B9],[@B10]\] by reanalysis of existing data restricted to the families with at least one case of CVID, in combination with additional fine-mapping \[[@B11]\]. Furthermore, genome-wide linkage analysis in a large multiplex CVID family revealed linkage to a locus on chromosomes 4q. This locus on 4q was replicated (requiring a lower standard of evidence than initial linkage) in a large cohort of small families \[[@B12]\].

Thus, there is considerable genetic heterogeneity in CVID, which mirrors the variable clinical presentation of the disease. Despite these conundrums, the discovery of genetic defects in ICOS \[[@B13],[@B14]\], TACI/*TNFRSF13B*\[[@B15],[@B16]\] and CD19 \[[@B17]\] provides proof that defects in single genes are associated with a CVID phenotype and underscores the value of candidate gene approaches in CVID. Furthermore, a considerable number of patients carrying mutations in the above mentioned genes were derived from familial cases showing recessive patterns of inheritance and sometimes involving consanguinity. The only CVID gene for which heterozygous mutations have been found in sporadic patients is TACI/*TNFRSF13B*\[[@B15],[@B18]\].

We therefore, focused in our candidate gene approach primarily on familial CVID cases and multiplex CVID/sIgAD families, which showed evidence for genetic linkage to the respective candidate gene loci based on available genotype data \[[@B9],[@B10]\]. We concentrated on cytokine/receptor pairs, which showed involvement in terminal B cell differentiation, preferential expression in germinal centers and involvement in class switch recombination. More importantly, the available knockout mouse models of the studied genes present with phenotypes that partially resemble aspects of human common variable immunodeficiency. A flow chart summarizing the study design and selection criteria for patients and candidate genes is provided in Figure [1](#F1){ref-type="fig"}.

![Selection of patients and candidate genes.](1471-2172-9-3-1){#F1}

In BCMA/*TNFRSF17*-deficient mice, the generation of long lived plasma cells in the bone marrow is severely impaired \[[@B19]\], which mirrors pathology observed in individuals with CVID \[[@B20]\]. APRIL/*TNFSF13*is an important factor that drives both human and murine B cells to induce Ig heavy chain class switch to IgA and IgG \[[@B21]\]. Moreover, *TNFSF13*-deficient mice show a selective deficiency in IgA \[[@B22]\].

Interleukin 10 (IL10) is an important immunoregulatory cytokine, which supports terminal B cell differentiation and has potent anti-inflammatory effects. Furthermore, IL10 production by T cells is deficient in human ICOS deficiency \[[@B14]\], X-linked lymphoproliferative disease \[[@B23]\] and in subsets of CVID patients \[[@B24]\], further underscoring the potential involvement of IL10 in the pathogenesis of hypogammaglobulinemia. Finally, IL10-deficient mice develop inflammatory bowel disease, a condition reminiscent of what can be observed in patients with CVID \[[@B3]\].

Signaling via IL21 and the IL21 receptor can induce apoptosis in B cells \[[@B25]\]. However, the interaction is also crucial for terminal B cell differentiation \[[@B26],[@B27]\]. The ability of IL21 to drive plasma cell differentiation makes this gene an attractive candidate gene for human CVID.

Chemokine (C-C motif) ligand 18 (CCL18) is a potent chemoattractant for T cells and B cells, highly expressed in germinal centers of secondary lymphoid organs by dendritic cells \[[@B28]\].

Results
=======

The genetic localization of the investigated genes, the number of exons, the genotyping markers and the families which were analyzed are summarized in Table [1](#T1){ref-type="table"}. The pedigrees of all families analyzed in this study are shown in Figure [2](#F2){ref-type="fig"}. Primers used for amplification and sequencing are listed in Table [2](#T2){ref-type="table"}.

###### 

Investigated candidate genes and analyzed families.

  Gene              Chromosomal location          Exons   Markers used for genotyping                  Linkage-positive CVID families for the respective locus   Autosomal recessive CVID families                           \# of sporadic CVID patients
  ----------------- ----------------------------- ------- -------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------- ------------------------------
  BCMA/*TNFRSF17*   16p13.1 11.9 Mb--12.0 Mb      3       D16S423, D16S407, D16S405                    cv22, cv72, cv73, cv91, cv128, cv135, cv136               fr6, fr16, fr17, fr19, fr20, fr21, fr22, fr23, fr24, cv32   50
  APRIL/*TNFSF13*   17p13.1 7.4 Mb                6       D17S513, D17S786                             cv73, cv97, cv137                                         fr6, fr17, fr18, fr20, fr21, fr22, fr23, fr24, fr27         NA
  *IL10*            1q31-q32 205 Mb               5       D1S1660, D1S1678, D1S1663, D1S2141, D1S229   cv73, cv77, cv125, cv128, cv136                           fr6, fr16--fr26, fr28                                       5 (IBD)
  *IL10RA*          11q23.3 117.3 Mb--117.4 Mb    7       D11S927, D11S925, D11S934                    cv18, cv53, cv72, cv75, cv136                             fr6, fr16--fr23, fr25, fr26, cv32                           5 (IBD)
  *IL10RB*          21q22.11 33.5 Mb--33.6 Mb     7       D21S265, D21S65, D21S219, D21S270, D21S167   cv4, cv22, cv32, cv75, cv80, cv128                        fr6, fr16, fr17, fr18                                       4 (IBD)
  *IL21*            4q26-q27 123.7 Mb--123.8 Mb   5       D4S430, D4S427                               cv4, cv52, cv53, cv59, cv74, cv135                        fr6, fr16--fr26, fr28--fr33, cv32                           NA
  *IL21R*           16p11 27.3 Mb--27.4 Mb        9       D16S420, D16S261, D16S411                    cv4, cv22, cv72, cv77, cv137                              fr6, fr16--fr26, fr28--fr33, cv32                           NA
  *CCL18*           17q11.2 31.4 Mb               3       D17S798, D17S250                             cv18, cv78, cv80, cv93, cv125, cv136                      fr6, fr16--fr26, fr28                                       NA

IBD, sporadic CVID patients with symptoms of inflammatory bowel disease; NA, not applicable.

###### 

Primer sequences for candidate genes.

  **Gene**   **Exon**   **Forward primer**         **Reverse primer**         **bp**^§^   **°C**^§^
  ---------- ---------- -------------------------- -------------------------- ----------- -----------
  *APRIL*    1          CCTTGCTACCCCACTCTTGA       TCTCTTGCACCCCCTTGAA        402         62
             2          CTGGGAAAAGGTGCGTGAGA       TGAGGAGAGAAGGAGGGAATC      337         62
             3          AGCAGCGTGGGGATTGTAA        CTCAGGTGCTTTTTGGTTCTTT     268         62
             4          AAGTGGATGCGGCTGAGATT       GGGAAGGGAGATGTTGAAGAA      536         62
             5          CATACCAAACCCAGCAGAC        GTTTCCAACCTCCCTCCTA        335         62
             6          GCGGGTCTGAGGAGTGAAGT       AGTCTAGGGGGTGGGAATGA       415         62
  *BCMA*     1          GTCTATCTCCCTGGCACCTCTCAC   CACTGCCTTGCTTCCTTTCTCTTT   685         55
             2          CGGGAGGCTGAGGCAGGAG        TCGAAAGGGCTGTAACGAAGTGAA   451         55
             3          TCCCGACTGCTCTGTAGGCTAACG   TTCTTTCCCCCTCCCACCTTTCTC   797         57
  *CCL18*    1          ATCCCTGGGTGCTTCCAACTC      TGCCCAGGGAGCCATCAA         414         57
             2          CCAAGCGGTGATATCTCCCAGTTC   AGGCCTTCCCCAAATGTCTCAGA    477         60
             3a         GAGGCCCCTGCAGTGTTTTGTG     CTGGGCATAGCAGATGGGACTCTT   498         60
             3b         GCAGGGGCCACAGGATTCC        TGCCCCTTTTCATATTTCCCTACT   680         57
  *IL10*     1          GTGCCGGGAAACCTTGATTGTGG    GGGGGAATAGGTGTTGGGGATGG    435         60
             2 and 3    GGGCATCAAAAAGACCGCATTTCA   CCCCCAACGCCTGCTCAAAGA      763         60
             4          CCACCAGCTTGTCCCCTAAGTGTG   TGGCCGGCCAGCCTAACC         404         59
             5          AGCATGAGGGAGGGGAGCCTATTT   GCGCCCGGCCTAGAACCAA        781         57
  *IL10RA*   1          CGCTAGCGCCCCAGGACAG        GTTTGCGGGTTGGGGGTTTG       545         64
             2          ATGTGCCCACTCTGCCCCTTACG    GGGCCCTCAGGCACTCACTTCATT   377         61
             3          GGGCTGTCCCAGTTTCTCCCAATG   CCCAACCCACCCCAAGACCTCTC    542         61
             4          CAAAGTCTCGGCGGGGACACC      CCTCCTCTGCCCACCCACCAT      388         61
             5          AGGCCCACCAGCTCTCAGTGTCC    CCAGGTGCACGCGTTTTGGATT     302         60
             6          CTTGGGCCACTCACTGAATGGTT    CCCACAGCGCTTGATGAAGGTAT    404         60
             7          CCTTCCCCGGCAGCACTGG        GCAGAGGAGCAGGCATGGCTAAAA   1048        63
  *IL10RB*   1          GCGCCTTTCAAAGCTTGCGAGGAT   GGCCGTGGCGTTTGCATCTTCTCT   442         65
             2          ACCCACGTGGCCTTTGAAGACAT    GTGGCCACGAGAATTTCCCAGAC    416         60
             3          CCAGTCAGCCTCAGGGAGAC       GGGCCCCAACATAGTCACAT       486         54
             4          ACTTCCGTGGACTAATTGTTCTGC   CTTCAGGGAGGGAAAGGTCTG      494         55
             5          AGTCCCCCAAAGTGCTGTGATTAC   GGGCGATAGATTTCTGAACTGAGC   575         57
             6          TCTGAGACGTCCCCCAAGATAAAC   TGGGCAGCCCTAACTAGAAAGGAA   359         57
             7          CCAGCCAGGAGTTCTGTGAAAA     TAGATGTGGGGCTGGCTCAGAT     382         57
  *IL21*     1 and 2    AGTTACTCACATTCATCCAT       CTGTCTCAGCAATACTACTT       736         50
             3          GAAATAGAGGATTGGGAAAG       GGTAAGGAAGACACCAGCAG       345         50
             4 and 5    TACAAGGACTTTTTCCATTG       GACTTTGCACACTTATGAGT       510         50
  *IL21R*    1          TCTCTGCTGAGTGACCGTAAG      TTCCTTCCCCAGCCCGCTACA      675         58
             2          CAGCAAGGGCAAAATAGTCAG      TGTCTACCGCTTCTGTTTCAT      898         57
             3          TTGGGACATTTTCAGCATAGC      ACCATTCATGGGAAGCGTGTA      863         59
             4          TGCTGCCCTAAATGAGGTAGT      AAAATTAGCTGGGTGTAGTGG      610         59
             5          AGATGGGGTTTCACCGTGTTA      TGCTCGTGCCCTTGGTCTCTG      699         55
             6          TTGCTAAGATGTCTGTAGTTA      GGGAAATGGGTCTGGGGTAGA      1067        55
             7          CCCTGTTTTTCAGACGAGATA      TTCAGAGGTGTGGACTATTAC      755         55
             8          GTGAAGAGGTGGCTGTAATAG      AGATGGGGAGGCGGAGTGGTG      768         55
             9          AGTGAACCGAGATGGCACCAC      AGGGAGGACGGCTGTTGTCAT      1270        59

IBD, sporadic CVID patients with symptoms of inflammatory bowel disease; NA, not applicable.

![**Pedigrees of CVID families**. Left column: pedigrees of analyzed autosomal recessive CVID families; right column: pedigrees of selected CVID families based on positional reasoning with respect to candidate loci; symbols: circles, female; squares, male; filled symbols, affected individual; slash, deceased.](1471-2172-9-3-2){#F2}

Table [3](#T3){ref-type="table"} summarizes the observed sequence variations, the *in silico*analysis of missense mutations by SIFT \[[@B29]\] and Polyphen \[[@B30]\] and the genotype frequencies in the studied CVID cohort compared to healthy donors.

###### 

Description and analysis of SNPs found in CVID patients

  Gene       SNP                 SIFT^\[30\]^        Polyphen^\[31\]^   CVID Genotypes   Healthy donors Genotypes   Additional studies                                           
  ---------- ------------------- ------------------- ------------------ ---------------- -------------------------- -------------------- ------------- ------------- ----------- -----------------------------------
  *BCMA*     S81N                tolerated           benign             T/T              T/C                        C/C                  T/T           T/C           C/C         n.a.
             rs373496                                                   0                0,014                      0,986                0\*           0,050\*       0,950\*     
             synonymous (T159)   n.a.                n.a.               T/T              T/C                        C/C                  T/T           T/C           C/C         no aberrant
             rs2017662                                                  0,071            0,029                      0,900                0\*           0,136\*       0,864\*     splicing of mRNA
             synonymous (T175)   n.a.                n.a.               T/T              T/C                        C/C                  T/T           T/C           C/C         no aberrant
             rs2071336                                                  0,071            0,029                      0,900                0\*           0,117\*       0,883\*     splicing of mRNA
             K179Q               **not tolerated**   benign             C/C              C/A                        A/A                  C/C           C/A           A/A         no segregation, normal expression
                                                                        0                0,014                      0,986                n.k.          n.k.          n.k.        
  *APRIL*    G67R                tolerated           benign             A/A              A/G                        G/G                  A/A           A/G           G/G         n.a.
             rs11552708                                                 0                0,190                      0,810                0,033\*       0,233\*       0,733\*     
             N96S                tolerated           benign             G/G              G/A                        A/A                  G/G           G/A           A/A         n.a.
             rs3803800                                                  0,632            0,316                      0,053                0,683\*       0,183\*       0,133\*     
  *IL10*     3\' UTR             n.a.                n.a.               C/C              C/T                        T/T                  C/C           C/T           T/T         n.a.
             rs3024496                                                  0,210            0,368                      0,421                0,293\*       0,500\*       0,207\*     
  *IL10RA*   synonymous (A153)   n.a.                n.a.               A/A              A/G                        G/G                  A/A           A/G           G/G         n.a.
             rs2256111                                                  0,154            0,346                      0,500                0,328\*       0,448\*       0,224\*     
             I224V               tolerated           benign             A/A              A/G                        G/G                  A/A           A/G           G/G         n.a.
             rs17121493                                                 0,846            0,154                      0                    0,917\*       0,083\*       0\*         
  *IL21*     synonymous (C78)    n.a.                n.a.               G/G              G/A                        A/A                  G/G           G/A           A/A         n.a.
             rs4833837                                                  0,200            0,360                      0,440                0,174\*\*     0,522\*\*     0,304\*\*   
  *IL21R*    5\' UTR rs961914    n.a.                n.a.               T/T              T/C                        C/C                  Allele T      Allele C                  n.a.
                                                                        0,042            0,167                      0,792                0,140\*\*\*   0,860\*\*\*               
             T46M                tolerated           benign             T/T              T/C                        C/C                  T/T           T/C           C/C         n.a.
                                                                        0                0,042                      0,958                0             0,010         0,990       
             R275Q               tolerated           benign             A/A              A/G                        G/G                  A/A           A/G           G/G         n.a.
                                                                        0                0,042                      0,958                0             0,050         0,950       

The observed known and newly discovered SNPs are listed in the table. The table summarizes in silico analysis results by SIFT and Polyphen for missense mutations and the frequencies of SNPs in CVID patients versus healthy control populations. n.a., not applicable. n.k., not known. \* HapMap CEU, \*\* PGA-EUROPEAN-PANEL, \*\*\* CEPH

BCMA/*TNFRSF17*and APRIL/*TNFSF13*
----------------------------------

Seventeen probands of CVID families were analyzed. Seven of these families were selected due to being linkage-positive at the *TNFRSF17*locus on chromosome 16p (Table [1](#T1){ref-type="table"}). In addition, we expanded our mutation screening in BCMA/*TNFRSF17*to a larger cohort of 50 sporadic CVID cases. One previously described heterozygous single nucleotide polymorphism (SNP) was found in a proband of family cv22 in exon 2: Ser81Asp \[dbSNP: rs373496\]. In exon 3 two synonymous SNPs \[dbSNP: rs2017662 and rs2071336\] were found in homozygous state in five individuals (family fr24 and four sporadic cases) and in heterozygous state in probands of families cv73 and fr21. RT-PCR was performed but evidenced no alternative splicing products (data not shown). A novel variant was identified in exon 3: K179Q, which was present in one individual. The K179Q variant was present in the heterozygous state both in affected and healthy members of the family, which renders unlikely a contribution of this mutation to the pathogenesis of the hypogammaglobulinemia. Flow cytometric analysis confirmed normal expression of the protein (data not shown).

APRIL/*TNFSF13*was analyzed in the probands from 12 CVID families. The families cv73, cv97 and cv137 were linkage positive at the *TNFSF13*locus (Table [1](#T1){ref-type="table"}). Two previously described non-synonymous SNPs \[dbSNP: rs11552708 and rs3803800\], located in exon 1 and exon 2 respectively, were found in the studied cohort (Table [3](#T3){ref-type="table"}).

IL10, IL10 receptor α and IL10 receptor β
-----------------------------------------

The *IL10*gene was sequenced in 23 individuals. Of those, 13 represented autosomal recessive CVID families, five families were selected for being linkage-positive, and five were sporadic CVID cases showing a clinical phenotype compatible with inflammatory bowel disease (Table [1](#T1){ref-type="table"}). One previously described heterozygous SNP \[rs3024496\] located in the 3\'UTR of the *IL10*gene was found in frequencies comparable to that in healthy controls (Table [3](#T3){ref-type="table"}).

IL10 receptor α, encoded by *IL10RA*was analyzed in 22 individuals, of whom 12 belonged to autosomal recessive families, five were from linkage-positive families at the *IL10RA*locus, and five were sporadic CVID cases (Table [1](#T1){ref-type="table"}). The known synonymous SNP \[dbSNP: rs2256111\] in exon 4 and the SNP \[dbSNP: rs17121493\] in exon 5 (I224V) were observed in frequencies comparable to those which are reported for normal controls in public databases (Table [3](#T3){ref-type="table"}).

The *IL10RB*gene was analyzed in 14 CVID patients, 10 from CVID families (six of them linkage-positive at the *IL10RB*locus) and four sporadic CVID cases (Table [1](#T1){ref-type="table"}). We found no genetic alterations in the 7 exons of *IL10RB*.

IL21 and IL21 receptor
----------------------

The 5 exons of *IL21*were amplified and sequenced in 25 individuals (19 autosomal recessive CVID (AR-CVID) families and 6 autosomal dominant CVID families (AD CVID) that are linkage-positive at the *IL21*locus). In exon 3 of the *IL21*gene the synonymous change \[dbSNP: rs4833837\] was observed in a frequency comparable to that reported in public databases (Table [3](#T3){ref-type="table"}).

The *IL21R*gene was analyzed in 24 individuals (19 AR CVID families and 5 AD CVID families linkage-positive at the *IL21R*locus). In exon 1 of *IL21R*the SNP \[dbSNP: rs961914\] was observed in homozygous state in the proband from family fr18 and in heterozygous state in cv32, fr25, fr28 and fr29. In exon 5 of the *IL21R*gene we found a previously undescribed heterozygous SNP resulting in the replacement of a conserved threonine by methionine at position 46 in the proband from family cv4 (Figure [3](#F3){ref-type="fig"}). In addition, a new heterozygous change in exon 8 resulting in R275Q was found in the family cv72. Both heterozygous substitutions showed perfect segregation with the disease phenotype in these families (Figure [3](#F3){ref-type="fig"}). However, we subsequently screened a cohort of 100 healthy individuals with normal immunoglobulin levels and found respectively 2 (T46M) and 5 (R275Q) heterozygous individuals among them, suggesting that these two coding sequence changes may not be disease-associated.

![**Two new polymorphisms in the *IL21R*gene**. Left panel: pedigree of CVID family cv4 and sequence chromatogram of *IL21R*exon 5 showing a C to T transition (c.137 C \> T), resulting in T46M at the protein level; right panel: pedigree of CVID family cv72 and sequence chromatogram of *IL21R*exon 8 showing a G to A transition (c.824 G \> A), resulting in R275Q at the protein level; symbols: circles, female; squares, male; filled symbols, affected individual.](1471-2172-9-3-3){#F3}

CCL18
-----

The three exons of *CCL18*including the 5\'and 3\'untranslated region were amplified and analyzed in 19 probands including six from CVID families linkage-positive at the *CCL18*locus on chromosome 17 (Table [1](#T1){ref-type="table"}). No genetic alterations were found.

Discussion
==========

In recent years, genetic linkage analysis of selective IgA deficiency (sIgAD) and common variable immunodeficiency (CVID) has led to the identification of several susceptibility loci \[[@B10]-[@B12]\]. However, all four molecular genetic defects underlying CVID reported to date, namely ICOS \[[@B13]\], TACI \[[@B15],[@B16]\], CD19 \[[@B17]\] and BAFF-R \[[@B31]\] were identified by a candidate gene approach using either phenotypic or genetic screening of genes known to be involved in B cell homeostasis, B cell activation or the T- B cell interaction. In the case of TACI/*TNFRSF13B*, linkage analysis was used to identify one small CVID family with the same homozygous mutation in two individuals \[[@B15]\].

The success with four CVID candidate genes stimulated researchers to evaluate additional candidate genes that encode proteins in the pathways of ICOS, TACI, BAFF-R, and CD19 signaling \[[@B32],[@B33]\]. Here we report on the analysis of eight additional candidate genes in CVID, where no mutation was identified.

The candidacy of the genes encoding BCMA and APRIL was strong since their close relatives BAFF-R and TACI have recently been shown to be mutated in CVID \[[@B15],[@B16],[@B31]\]. Although both *TNFRSF17*and *TNFSF13*were shown to be polymorphic in the studied cohort, none of these changes were obviously disease related.

The genes encoding IL10 and its receptor subunits were selected as candidate genes for CVID, since we were able to show that IL10 is the critical cytokine missing in ICOS deficiency \[[@B16]\]. Furthermore, IL10 plays an important role in B cell development. However, no mutations were found in the investigated families.

In a context dependent manner IL21 is able to induce differentiation of plasma cells and memory cells, or is able to promote apoptosis of resting and anti-IgM-activated B cells \[[@B25]\]. Ettinger et al recently showed that IL21 costimulation in humans is capable of inducing substantial B-cell expansion, plasma cell differentiation from CD27+ memory B-cells and class switch recombination \[[@B27]\].

Therefore, we screened multiple families for mutations in *IL21*and/or *IL21R*. Apart from known SNPs we could identify two new heterozygous variations in IL21R that result in amino acid changes and segregated with the disease phenotype in families. However these changes were also found in a screening of healthy individuals. This suggests that these two variations may not be disease associated.

Conclusion
==========

In summary, we cannot provide evidence that the above listed eight genes are implicated in the etiology of CVID in this studied cohort of patients. However, only protein coding regions of the respective genes were analyzed leaving the possibility of mutations in promoter or regulatory regions. Based on other studies of humans and mice these genes remain attractive candidate genes for CVID. Larger CVID cohorts or cohorts of non-European origin may enable the identification of rare mutations in these genes.

Methods
=======

Notation convention used throughout this paper
----------------------------------------------

For several of the genes we mention, such as TACI/*TNFRSF13B*, the HUGO-approved gene acronym (*TNFRSF13B*) has no resemblance to the protein acronym (TACI), which is much more familiar to immunologists. In those cases, we use either the protein name alone or the compound notation protein/*gene*, when referring to either the gene or the protein it encodes.

Patients and families
---------------------

Twenty families with at least one case of CVID were selected from a collection of 101 multiplex CVID/IgA deficient families \[[@B5],[@B9],[@B10],[@B34]\], based in part on reanalysis of genotype data previously generated for genetic linkage studies. This method had successfully identified family A as consistent with linkage to the TACI/*TNFRSF13B*locus \[[@B15]\]. In addition, 19 autosomal recessive CVID families were collected at the Department of Rheumatology and Clinical Immunology in Freiburg, Germany, from 2001 to 2005. The families were considered as having possible recessive inheritance when two or more siblings in one generation were affected by CVID and their parents and children had normal immunoglobulin levels. Alternatively, ten families were considered as recessive because of a known consanguinity in these families. Six families originated from Turkey, five from Germany, four from Italy, two from the UK and one from Sweden. For the analysis of *TNFRSF17*, encoding BCMA, fifty additional individuals with sporadic CVID followed in the Department of Pediatrics, University of Brescia were included in this study. Informed written consent was obtained from each patient or parent guardians prior to participation under the internal ethics review board-approved clinical study protocol (ZERM, University Hospital Freiburg (\#239/99).

Linkage analysis
----------------

Genetic linkage analysis was carried out by computing LOD scores using a dominant model and imperfect penetrance using FASTLINK \[[@B35]-[@B37]\], as previously described \[[@B11]\]. We also tried a recessive model in which the penetrance for heterozygotes is assumed to be the same (0.05) as for individuals with no disease-associated alleles. For each candidate gene, we tried to find close flanking markers from the marker set chosen for the previous studies \[[@B9],[@B10]\]. The relevant markers near each gene are shown in Table [1](#T1){ref-type="table"}. We tried to find families with positive scores at all flanking markers, but sometimes had to settle for families with positive scores at one or some flanking marker(s) and 0 scores (either due to no genotypes or an uninformative marker) at some flanking marker(s). With the exceptions of cv32 and cv74, all the families are small and have maximum achievable scores under 1.0. Thus, the positive scores should be taken only as evidence that these families are consistent with linkage and preferred over families with negative LOD scores, but we make no claims of statistically significant linkage. Based on these criteria, the families which were consistent with linkage for each individual candidate gene were selected out of the previously described cohort \[[@B9],[@B10]\] (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}).

Sequencing of candidate genes
-----------------------------

Candidate genes were evaluated by sequencing the coding regions of the genes on genomic DNA including 20 bp of the flanking intronic or untranslated regions. All primers were sought with the aid of the Primer Select software (PE Applied Biosystems, Foster City, CA, USA); sequences are summarized in Table [2](#T2){ref-type="table"}. Genomic DNA was amplified by PCR and subsequently sequenced with the amplification primers. After gel electrophoresis on an ABI Prism™ 377 DNA Sequencer, the data was analyzed by the DNA Sequencing Analysis software, version 3.4 (PE Applied Biosystems) and Sequencer™, version 3.4.1 (Gene Codes Corporation, Ann Arbor, MI, USA).
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